http://orcid.org/0000-0003-1340-6416
References
- Dawson AH, Buckley NA. Pharmacological management of anticholinergic delirium – theory, evidence and practice. Br J Clin Pharmacol. 2016;81:516–524.
- Curry S, O’Connor A, Graeme K, et al. Neurotransmitters and neuromodulators. In: Hoffman R, Howland MA, Lewin N, Nelson L, Goldfrank L, editors. Goldfrank’s toxicologic emergencies. 10th ed. New York: McGraw-Hill; 2015. p. 176.
- Zerbo E, Kondracke A, Psychiatric principles. In: Hoffman R, Howland MA, Lewin N, Nelson L, Goldfrank L, editors. Goldfrank’s toxicologic emergencies. 10th ed. New York: McGraw-Hill; 2015. p. 350–351.
- Dale H. Chemical transmission of the effects of nerve impulses. Br Med J. 1934;1:835–841.
- Kleinwachter. Beobachtung uber die Wirkung des Calabar-Extracts gegen Atropin-vergiftung. Berliner Klin Wochenschrift. 1864;1:369–371.
- Nickalls RWD, Nickalls EA. The first use of physostigmine in the treatment of atropine poisoning: a translation of Kleinwachter’s paper entitled “Observations on the effect of Calabar bean extract as an antidote to atropine poisoning.” Anaesthesia. 1988;43:776–777.
- Forrer GR, Miller JJ. Atropine coma: a somatic therapy in psychiatry. Am J Psychiatry. 1958;115:455–458.
- Watkins JW, Schwarz ES, Arroyo-Plasencia AM, et al. The use of physostigmine by toxicologists in anticholinergic toxicity. J Med Toxicol. 2015;11:179–184.
- Hoffman RS, Goldfrank LR. The poisoned patient with altered consciousness. Controversies in the use of a “coma cocktail.” J Am Med Assoc. 1995;274:562–569.
- Munoz RA. Treatment of tricyclic intoxication. Am J Psychiatry. 1976;133:1085–1087.
- Walker WE, Levy RC, Hanenson IB. Physostigmine – its use and abuse. JACEP. 1976;5:436–439.
- Rumack BH. Anticholinergic poisoning: treatment with physostigmine. Pediatrics 1973;52:449–451.
- Pentel P, Peterson CD. Asystole complicating physostigmine treatment of tricyclic antidepressant overdose. Ann Emerg Med. 1980;9:588–590.
- Burns MJ, Linden CH, Graudins A, et al. A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med. 2000;35:374–381.
- Schneir AB, Offerman SR, Ly BT, et al. Complications of diagnostic physostigmine administration to emergency department patients. Ann Emerg Med. 2003;42:14–19.
- Rasimas JJ, Ph D, Sachdeva KK, et al. Revival of an antidote: bedside experience with physostigmine. J Am Assoc Emerg Psychiatry. 2014;12:5–24.
- Arens AM, Shah K, Al-Abri S, et al. Safety and effectiveness of physostigmine: a 10-year retrospective review. Clin Toxicol. 2017;56:1–7.
- Nguyen TT, Armengol C, Wilhoite G, et al. Adverse events from physostigmine: an observational study. Am J Emerg Med. 2018;36:141–142.
- Martel M, Sterzinger A, Miner J, et al. Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam. Acad Emerg Med. 2005;12:1167–1172.
- R Development Core Team R. R software. Environ Stat Comput. 2017. Available from: https://www.R-project.org/
- Stellpflug S, Cole J, Isaacson B, et al. Massive atropine eye drop ingestion treated with high-dose physostigmine to avoid intubation. West J Emerg Med. 2012;13:77–79.
- Cole JB, Stellpflug SJ, Ellsworth H, et al. Reversal of quetiapine-induced altered mental status with physostigmine: a case series. Am J Emerg Med. 2012;30:950–953.
- Hendrickson R, Howland MA, n-Acetylcysteine. In: Hoffman R, Howland MA, Lewin N, Nelson L, Goldfrank L, editors. Goldfrank’s toxicologic emergencies. 10th ed. New York: McGraw-Hill; 2015. p. 465–72.
- Hoffman RS. Understanding the limitations of retrospective analyses of poison center data. Clin Toxicol (Phila). 2007;45:943–945.